Evidence map›Paper›PMID 23783065›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Carolyn I Rodriguez, Lawrence S Kegeles, Amanda Levinson, Tianshu Feng, Sue M Marcus, Donna Vermes, Pamela Flood, Helen B Simpson

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 137 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 5 pooled it
20.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01100255 phase2completednot on this map

Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine

TypeinterventionalSponsorNew York State Psychiatric InstituteRan2010 to 2015Enrolled15ConditionsObsessive-Compulsive DisorderArmsKetamine infusion, Saline
NCT02422290 phase1 / phase2completednot on this mapstarted 2015, after this paper: background citation

Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)

TypeinterventionalSponsorNew York State Psychiatric InstituteRan2015 to 2020Enrolled5ConditionsObsessive-Compulsive DisorderArmsKetamine
3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 5 syntheses or guidelines pooled it, 364 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.Journal of the American Academy of Child and Adolescent Psychiatry · 2015
    Pooled it
  6. Trial
  7. Trial
  8. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  9. Trial
  10. Trial
  11. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Heterogeneous neuroimaging findings in obsessive-compulsive disorder converge to a common brain network using coordinate network mapping.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  19. Review
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Carolyn I Rodriguez1] New York State Psychiatric Institute, New York, NY, USA [2] Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY, USA.
Lawrence S Kegeles
Amanda Levinson
Tianshu Feng
Sue M Marcus
Donna Vermes
Pamela Flood
Helen B Simpson
New York Psychoanalytic Society and Institute · USNew York State Psychiatric InstituteColumbia University · USUniversity of California, San Francisco · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
Novel Interventions for Adults with Obsessive-Compulsive DisorderK23MH092434 · NIMH · STANFORD UNIVERSITY · PI RODRIGUEZ, CAROLYN I · 2011 to 2015
$805k
Enhancing Patient-Oriented Research and Training in OCDK24MH091555 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SIMPSON, HELEN BLAIR · 2010 to 2014
$742k
NCRR NIH HHS UL1 RR024156NIMH NIH HHS K23 MH092434NIMH NIH HHS K23MH092434NIMH NIH HHS K24MH09155NIMH NIH HHS K24 MH091555
6 · The paper itself

Abstract

Serotonin reuptake inhibitors (SRIs), the first-line pharmacological treatment for obsessive-compulsive disorder (OCD), have two limitations: incomplete symptom relief and 2-3 months lag time before clinically meaningful improvement. New medications with faster onset are needed. As converging evidence suggests a role for the glutamate system in the pathophysiology of OCD, we tested whether a single dose of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, could achieve rapid anti-obsessional effects. In a randomized, double-blind, placebo-controlled, crossover design, drug-free OCD adults (n=15) with near-constant obsessions received two 40-min intravenous infusions, one of saline and one of ketamine (0.5 mg/kg), spaced at least 1-week apart. The OCD visual analog scale (OCD-VAS) and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) were used to assess OCD symptoms. Unexpectedly, ketamine's effects within the crossover design showed significant (p<0.005) carryover effects (ie, lasting longer than 1 week). As a result, only the first-phase data were used in additional analyses. Specifically, those receiving ketamine (n=8) reported significant improvement in obsessions (measured by OCD-VAS) during the infusion compared with subjects receiving placebo (n=7). One-week post-infusion, 50% of those receiving ketamine (n=8) met criteria for treatment response (≥35% Y-BOCS reduction) vs 0% of those receiving placebo (n=7). Rapid anti-OCD effects from a single intravenous dose of ketamine can persist for at least 1 week in some OCD patients with constant intrusive thoughts. This is the first randomized, controlled trial to demonstrate that a drug affecting glutamate neurotransmission can reduce OCD symptoms without the presence of an SRI and is consistent with a glutamatergic hypothesis of OCD.

Indexed as

AdultCross-Over StudiesDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleHumansKetamineMaleMiddle AgedObsessive-Compulsive DisorderYoung AdultExcitatory Amino Acid AntagonistsKetamine

Identifiers

PMID23783065
PMCPMC3799067
OpenAlexW2084290400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.